Advanced NSCLC Patients with EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit from Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy
Frontiers in Oncology(2021)
Key words
non-small cell lung cancer,liquid biopsy,gene sequencing,epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),drug resistance
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined